Strategic report seeks urgent IP reforms in Australia
This article was originally published in Scrip
The same week it bemoaned market conditions for pharma firms, the R&D-based industry association, Medicines Australia, has applauded a government backed report outlining a 10-year strategic health and medical research plan for Australia. The clearest call in the report is for Australia’s intellectual property system should be harmonized with international standard by extending the term of pharmaceutical data exclusivity. The report itself says its plan should be treated as an urgent national priority. And Medicines Australia agrees: CEO Brendan Shaw said the recommendations deserved bi-partisan support and that they should be implemented "expeditiously.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.